Watkins Tim
SEC CIK 2065965 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| CTNM | Contineum Therapeutics, Inc. | CMO, Head of Development | 19.8K | — | $322.6K | 8 | 2025-12-29 | 2026-06-30 |
Most active insiders at CTNM, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Lorrain Daniel S. | CSO | — | $1.13M |
| 2 | Stengone Carmine N. | CEO, Pres, Dir | — | $401.4K |
| 3 | Watkins Tim | CMO, Head of Development | — | $322.6K |
Transactions 8
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-07-01 19:04 | 2026-06-30 | CTNM | Contineum Therapeutics, Inc. | Watkins Tim | CMO, Head of Development | M - OptEx | $4.50 | +10.8K | 19.8K | +121% | +$48.7K |
| DT | 2026-07-01 19:04 | 2026-06-30 | CTNM | Contineum Therapeutics, Inc. | Watkins Tim | CMO, Head of Development | S - Sale+OE | $16.02 | -10.8K | 8,961 | -55% | -$173.6K |
| D | 2026-03-02 | 2026-03-02 | CTNM | Contineum Therapeutics, Inc. | Watkins Tim | CMO, Head of Development | M - OptEx | $4.50 | +3,611 | 3,611 | New | +$16.2K |
| D | 2026-03-02 | 2026-03-02 | CTNM | Contineum Therapeutics, Inc. | Watkins Tim | CMO, Head of Development | S - Sale+OE | $15.02 | -3,611 | 0 | -100% | -$54.2K |
| DM | 2026-01-30 | 2026-01-28 | CTNM | Contineum Therapeutics, Inc. | Watkins Tim | CMO, Head of Development | S - Sale+OE | $14.18 | -3,611 | 0 | -100% | -$51.2K |
| D | 2026-01-30 | 2026-01-28 | CTNM | Contineum Therapeutics, Inc. | Watkins Tim | CMO, Head of Development | M - OptEx | $4.50 | +3,611 | 3,611 | New | +$16.2K |
| D | 2025-12-30 | 2025-12-29 | CTNM | Contineum Therapeutics, Inc. | Watkins Tim | CMO, Head of Development | S - Sale+OE | $12.06 | -3,611 | 0 | -100% | -$43.5K |
| D | 2025-12-30 | 2025-12-29 | CTNM | Contineum Therapeutics, Inc. | Watkins Tim | CMO, Head of Development | M - OptEx | $4.50 | +3,611 | 3,611 | New | +$16.2K |
Purchase Sale Sale after option exercise All abbreviations